top of page
CMML
PREACH-M Trial Update
Humanigen was honored to present progress from the PREACH-M trial evaluating lenzilumab in CMML today at AACR in Orlando, FL. #HGEN
Blood
Phase 1 study of lenzilumab, a recombinant
anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
Blood
A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor
(anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)
bottom of page